drugset / Trial / NCT03275974

Glutamine PET Imaging Colorectal Cancer

NCT03275974

Phase 1 Terminated 6 enrolled M.D. Anderson Cancer Center
NaSingle-groupOpen-labelDiagnostic

Summary

The clinical trial studies how well 11C-glutamine and 18F-FSPG positron emission tomography (PET) imaging works in detecting tumors in patients with metastatic colorectal cancer compared to standard imaging methods such as magnetic resonance imaging (MRI) or computed tomography (CT) scanning.

Timeline

Start
2021-04-27
Primary completion
2025-12-23
Completion
2025-12-23

Drugs

EvaluationDrugModalityDoseRoute
Subject 11C-Glutamine Diagnostic / imaging agent Intravenous
Subject 18F-FSPG Diagnostic / imaging agent Intravenous

Indications